Your browser does not support JavaScript!
print this page Print this page
text size


References

  1. SPRYCEL summary of product characteristics; September 2007.
  2. Hehlmann R, Hochhaus A, Baccarani M; European Leukemia Net. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342-350.
  3. Geary CG. The story of chronic myeloid leukaemia. Br J Haematol. 2000;110(1):2-11.
  4. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018-1029.
  5. O'Brien SG, Guilhot F, Larson RA, et al; IRIS investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
  6. Baccarani M, Russo D, Rosti G, Martinelli G. Interferon-alfa for chronic myeloid leukemia. Semin Hematol. 2003;40(1):22-33.
  7. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2006;108(6):1809-1820.
  8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Chronic Myelogenous Leukemia, V2.2009. Available at http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf. Accessed 29 October 2008.
  9. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol. 2007;44(1 suppl 1):S15-S24.
  10. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000;95(11):3498-3505.
  11. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101(6):2368-2373.
  12. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101(2):690-698.
  13. Shah NP. Medical management of CML. Hematology Am Soc Hematol Educ Program. 2007;2007:371-375.
  14. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637-1647.
  15. Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
  16. Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol. 2007;18(suppl 6):vi42-vi46.
  17. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008;111(3):1039-1043.
  18. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303-2309.
  19. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol. 2007;44(1 suppl 1):S25-S31.
  20. Tasigna (nilotinib) summary of product characteristics. Novartis.
  21. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505.
  22. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204-3212.
  23. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109(10):4143-4150.
  24. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose inatinib for chronic-phase myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109 (12):5143-5150.
  25. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8):3207-3213.
  26. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358-3363.

Disclaimer: This is an international Web site for SPRYCEL® (dasatinib) and is intended for healthcare professionals outside the U.S. If you are a U.S. resident, please visit www.SPRYCEL.com. If you are not a healthcare professional, please visit www.BMS.com. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located or practice.